fda decision tirzepatide approval approves new weight-loss drug Zepbound (tirzepatide) Eli Lilly Gets FDA Approval – Eli Lilly seeks FDA approval

Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent- mediated central mechanisms

that's a failed experiment

The trial tested multiple dose levels over 48 weeks, and the headline result, up to 24.2% body weight reduction at the highest dose, grabbed international attention

Cardiovascular outcome trials have established benefits for specific agents: the LEADER trial for liraglutide, SUSTAIN-6 for injectable semaglutide, and REWIND for dulaglutide demonstrated reduced risk of major adverse cardiovascular events in patients with type 2 diabetes

Available evidence suggests that fertility improvements observed during therapy stem largely from weight and insulin changes rather than a drug-specific reproductive effect